🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
547,09 USD
Máx. histórico
558,88
7 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,11%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+0,85%
Cierre anterior
542,50
Rango de hoy
531,53 – 548,76
Volumen hoy
1.271.214
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 35,21 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 4 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 01/06/2007 | 29,93 | 30,25 | 29,44 | 29,66 | -0,80% | 2,71% | 1.562.600 |
| 31/05/2007 | 30,03 | 30,16 | 29,52 | 29,90 | -0,76% | 2,13% | 1.816.900 |
| 30/05/2007 | 30,44 | 30,49 | 29,89 | 30,13 | -1,25% | 1,97% | 1.362.400 |
| 29/05/2007 | 30,47 | 30,75 | 30,14 | 30,51 | -0,46% | 2,00% | 934.900 |
| 25/05/2007 | 30,60 | 30,84 | 30,31 | 30,65 | +0,23% | 1,73% | 719.600 |
| 24/05/2007 | 31,34 | 31,45 | 30,40 | 30,58 | -2,80% | 3,35% | 2.141.900 |
| 23/05/2007 | 31,55 | 31,74 | 31,00 | 31,46 | +0,03% | 2,35% | 1.482.900 |
| 22/05/2007 | 31,55 | 31,75 | 31,35 | 31,45 | -0,51% | 1,27% | 1.085.400 |
| 21/05/2007 | 31,46 | 31,92 | 31,30 | 31,61 | +0,48% | 1,97% | 1.220.600 |
| 18/05/2007 | 31,41 | 31,56 | 30,83 | 31,46 | +0,19% | 2,32% | 1.951.000 |
| 17/05/2007 | 32,19 | 32,26 | 31,19 | 31,40 | -2,94% | 3,32% | 1.838.100 |
| 16/05/2007 | 31,73 | 32,37 | 31,34 | 32,35 | +2,11% | 3,25% | 2.156.800 |
| 15/05/2007 | 30,47 | 32,06 | 30,23 | 31,68 | +4,14% | 6,01% | 3.894.300 |
| 14/05/2007 | 30,05 | 30,75 | 29,95 | 30,42 | +1,16% | 2,66% | 1.522.400 |
| 11/05/2007 | 29,58 | 30,12 | 29,40 | 30,07 | +1,48% | 2,43% | 1.565.300 |
| 10/05/2007 | 30,37 | 30,45 | 29,48 | 29,63 | -3,26% | 3,19% | 2.017.900 |
| 09/05/2007 | 30,10 | 30,76 | 29,94 | 30,63 | +1,22% | 2,72% | 2.265.300 |
| 08/05/2007 | 30,31 | 30,42 | 29,63 | 30,26 | -0,53% | 2,61% | 1.901.400 |
| 07/05/2007 | 30,68 | 30,76 | 30,33 | 30,42 | -0,16% | 1,40% | 1.196.300 |
| 04/05/2007 | 30,84 | 30,97 | 30,10 | 30,47 | -0,97% | 2,82% | 805.900 |
| 03/05/2007 | 30,60 | 30,85 | 30,15 | 30,77 | +0,13% | 2,29% | 825.500 |
| 02/05/2007 | 30,18 | 31,00 | 30,08 | 30,73 | +1,79% | 3,05% | 1.557.700 |
| 01/05/2007 | 30,75 | 30,89 | 29,67 | 30,19 | -1,79% | 3,97% | 2.136.700 |
| 30/04/2007 | 31,43 | 31,53 | 30,70 | 30,74 | -1,98% | 2,64% | 1.206.100 |
| 27/04/2007 | 31,32 | 31,55 | 31,00 | 31,36 | -0,25% | 1,76% | 981.000 |
| 26/04/2007 | 31,07 | 31,50 | 30,89 | 31,44 | +0,35% | 1,96% | 1.125.400 |
| 25/04/2007 | 31,04 | 31,34 | 30,76 | 31,33 | +0,38% | 1,87% | 2.060.500 |
| 24/04/2007 | 31,55 | 31,55 | 30,75 | 31,21 | -1,05% | 2,54% | 1.261.600 |
| 23/04/2007 | 31,33 | 31,86 | 30,84 | 31,54 | -1,07% | 3,26% | 2.078.000 |
| 20/04/2007 | 31,47 | 31,99 | 31,09 | 31,88 | +2,71% | 2,86% | 2.184.600 |